Top 10 Biotech Stocks To Buy For 2019

What happened

Shares of Intrexon Corporation (NYSE:XON) slipped as much as 12.9% on Friday morning and were down 7.9% as of 11:40 a.m. EDT due to a surprise delay in reporting its second-quarter financial results. The biotech was scheduled to announce its Q2 earnings results on Aug. 9, 2018, but instead said it wouldn’t report the final results and would also delay the filing of its quarterly report to the Securities and Exchange Commission (SEC).

Intrexon stated that the delay was due to its implementation of the Accounting Standards Codification (ASC) Topic 606 regulations related to revenue recognition that went into effect on Jan. 1, 2018. The company said it would file its Q2 quarterly report “within the next few days” and would also be filing an amended Q1 report. 

Image source: Getty Images.

Top 10 Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.

  • [By Motley Fool Staff]

    Alnylam’s (NASDAQ:ALNY) Onpattro is the first Food and Drug Administration (FDA)-approved RNAi therapy. However, competition is fast approaching and could make it difficult for Alnylam to pocket profits. Can Onpattro carve out significant sales as a treatment for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis?

  • [By Jim Crumly]

    Drug giant Pfizer released details of a successful trial of a drug for heart damage from a rare disease, and although that company’s stock had little reaction, falling 1.9%, shares of companies with potentially competing drugs reacted sharply. Alnylam Pharmaceuticals (NASDAQ:ALNY) soared 16.2%, Ionis Pharmaceuticals (NASDAQ:IONS) jumped 7.8%, and Eidos Therapeutics (NASDAQ:EIDX) plunged 31.1%.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit

Top 10 Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Cory Renauer]

    Biogen Inc.’s (NASDAQ:BIIB) Alzheimer’s disease hopeful topped the list last year, but repeated failures with experimental drugs that attack the disease from a similar angle have all flopped. Despite the risk, EvaluatePharma estimates aducanumab’s present value at around $8.4 billion and this figure will rise or fall dramatically when the company reads off results of ongoing pivotal trials, probably in early 2020.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings report from partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was released for IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

  • [By George Budwell]

    The spark? Nightstar’s shares are bolting higher in response to an $877 million buyout offer from biotech heavyweight Biogen (NASDAQ:BIIB). Per the terms of the agreement, Biogen will pay $25.50 in cash for each share of Nightstar, which translates to a hefty 68% premium when compared to where the gene therapy company’s shares closed on Friday. According to the two companies, this transaction should close by midyear.

  • [By Steve Symington]

    But several individual stocks lagged the broader market. Read on to see why Cerner (NASDAQ:CERN), Biogen (NASDAQ:BIIB), and Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) slumped today.

Top 10 Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Thursday was another down day for the stock market, with new pressure coming from international moves on the macroeconomic front. The European Central Bank signaled that it was ready to provide more accommodative monetary policy, reversing a previous tightening stance and showing its concerns about the prospects for economic growth in the region. Yet favorable earnings reports continued lifting shares of certain individual companies. Rosetta Stone (NYSE:RST), ArQule (NASDAQ:ARQL), and Fly Leasing (NYSE:FLY) were among the top performers. Here’s why they did so well.

  • [By Motley Fool Transcribers]

    Arqule Inc  (NASDAQ:ARQL)Q4 2018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:


  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

Top 10 Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.78 million shares from the previous level of 9.98 million. Shares were last seen trading at $196.64, in a 52-week trading range of $163.31 to $201.23.

  • [By Cory Renauer]

    The recent surge in biotech investment is terrific for the pace of innovation, but that capital isn’t heading toward the industry’s bigger older players, a couple of which are looking mighty underappreciated right now. Perhaps the investment community’s intense focus on start-ups has created interesting opportunities to snap up shares of these two overlooked biotechs at a very nice price.

    Company (Symbol) Forward P/E Ratio Free Cash Flow, Past 12 Months Cash, Cash Equivalents, and Short-Term Investments as of March 31
    AbbVie Inc. (NYSE:ABBV) 12.2 $10.0 billion $9.5 billion
    Amgen, Inc. (NASDAQ:AMGN) 14.2 $10.9 billion $32.2 billion

    Data source: Yahoo! Finance.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.98 million shares from the previous level of 10.31 million. Shares were last seen trading at $193.97, in a 52-week trading range of $163.31 to $201.23.

  • [By Jon C. Ogg]

    In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) shares made a slight gain on Tuesday after it was announced that the U.S. Food and Drug Administration (FDA) approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. Specifically, the agency approved Prolia (denosumab), driven by positive late-stage results.

  • [By Joseph Griffin]

    In other news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the transaction, the director now owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,777 shares of company stock valued at $4,648,718. Insiders own 0.27% of the company’s stock.

    COPYRIGHT VIOLATION WARNING: “Boston Financial Mangement LLC Has $3.86 Million Stake in Amgen, Inc. (AMGN)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at

    Amgen Profile

Leave a Reply

Your email address will not be published. Required fields are marked *